Prevalence of Cardiovascular Comorbidities in Coronavirus Disease 2019, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome: Pooled Analysis of Published Data
Open Access
- 1 September 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (17) , e016812
Abstract
Background: Coronavirus disease 2019 (COVID‐19) is spreading widely around the world. We conducted this meta‐analysis to explore the prevalence of cardiovascular comorbidities in COVID‐19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS) cases. Methods and Results: Relevant reports updated to April 17, 2020, were searched from PubMed, Embase, Web of Science, and the Cochrane Library with no restriction on language. A random‐effects model was used in this meta‐analysis to obtain pooled proportions of cardiovascular comorbidities in COVID‐19, SARS, and MERS. A total of 22 studies (12 for COVID‐19, 4 for SARS, and 6 for MERS) were included in this analysis, and the average age of patients with COVID‐19, SARS, and MERS was 46.41±1.79, 39.16±2.25, and 52.51±4.64 years, respectively. Proportions of cardiovascular comorbidities in coronavirus diseases were as follows: COVID‐19: proportion of hypertension was 17.1% (95% CI, 13.2%–20.9%), proportion of cardiac disease was 4.5% (95% CI, 3.6%–5.5%) and proportion of diabetes mellitus was 8.5% (95% CI, 5.5%–11.4%); SARS: proportion of hypertension was 4.5% (95% CI, 2.0%–7.0%), proportion of cardiac disease was 2.1% (95% CI, 0.6%–3.7%) and proportion of diabetes mellitus was 3.7% (95% CI, 1.0%–6.4%); MERS: proportion of hypertension was 30.3% (95% CI, 18.3%–42.2%), proportion of cardiac disease was 20.9% (95% CI, 10.7%–31.1%), and proportion of diabetes mellitus was 45.4% (95% CI, 27.3%–63.5%). Conclusions: The prevalence of cardiovascular comorbidities varies among different coronavirus‐associated diseases. With the development of time, proportions of cardiovascular comorbidities in COVID‐19 need further attention.Keywords
This publication has 28 references indexed in Scilit:
- Community Case Clusters of Middle East Respiratory Syndrome Coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: A Descriptive Genomic studyInternational Journal of Infectious Diseases, 2014
- Middle East Respiratory Syndrome Coronavirus: A Case-Control Study of Hospitalized PatientsClinical Infectious Diseases, 2014
- Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus InfectionAnnals of Internal Medicine, 2014
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Hematological and Biochemical Factors Predicting SARS Fatality in TaiwanJournal of the Formosan Medical Association, 2006
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Left Ventricular Performance in Patients With Severe Acute Respiratory SyndromeCirculation, 2003
- Severe Acute Respiratory Syndrome: Clinical Outcome and Prognostic CorrelatesEmerging Infectious Diseases, 2003
- Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)Thorax, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongNew England Journal of Medicine, 2003